# An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

> **NCT03801278** · — · NO_LONGER_AVAILABLE · sponsor: **Five Prime Therapeutics, Inc.**

## Conditions studied

- Recurrent Bladder Cancer

## Interventions

- **DRUG:** FPA144

## Key facts

- **NCT ID:** NCT03801278
- **Lead sponsor:** Five Prime Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03801278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03801278, "An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03801278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*